Form D · Biotechnology
Alpine Immune Sciences, Inc.
Seattle, WA · CIK 0001632083
Offering snapshot reported Jul 24, 2017 · SEC filing
- Reported sold
- $17M Offering amount: $17M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 24, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 24, 2017 | Initial | $17,000,004 | No comparison | 3 | SEC filing |
| Jun 21, 2016 | Initial | $10,333,333 | No comparison | 3 | SEC filing |
| May 13, 2015 | Amendment | $1,250,000 | $250,000vs Feb 5, 2015 | 1 | SEC filing |
| Feb 5, 2015 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-291377
Source: Form D, filed Jul 24, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dr. Mitchell H Gold | Director, Executive |
| Mitchell H. Gold | Director, Executive |
| Michael Kornacker | Executive |
| David Miller | Executive |
| Stanford Pang | Executive |
| J. Paul Rickey | Executive |
| Ryan Swanson | Executive |
| Peter Thompson | Director |
| James Topper | Director |
| Jay Venkatesan | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
201 Elliott Ave W Suite 230
Seattle, WA, 98119
Seattle, WA, 98119